Ho Thi-Luu, Mutalik Chinmaya, Rethi Lekshmi, Nguyen Huynh-Ngoc Truc, Jheng Pei-Ru, Wong Chin-Chean, Yang Tzu-Sen, Nguyen Thi Thuy, Mansel Bradley W, Wang Chen-An, Chuang Er-Yuan
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan; International Ph.D. Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Int J Biol Macromol. 2023 Apr 30;235:123821. doi: 10.1016/j.ijbiomac.2023.123821. Epub 2023 Mar 2.
A combination of chemotherapy and chemodynamic therapy (CDT) is being developed to improve the theranostic efficacy and biological safety of current therapies. However, most CDT agents are restricted due to complex issues such as multiple components, low colloidal stability, carrier-associated toxicity, insufficient reactive oxygen species generation, and poor targeting efficacy. To overcome these problems, a novel nanoplatform composed of fucoidan (Fu) and iron oxide (IO) nanoparticles (NPs) was developed to achieve chemotherapy combined with CDT synergistic treatment with a facile self-assembling manner, and the NPs were made up of Fu and IO, in which the Fu was not only used as a potential chemotherapeutic but was also designed to stabilize the IO and target P-selectin-overexpressing lung cancer cells, thereby producing oxidative stress and thus synergizing the CDT efficacy. The Fu-IO NPs exhibited a suitable diameter below 300 nm, which favored their cellular uptake by cancer cells. Microscopic and MRI data confirmed the lung cancer cellular uptake of the NPs due to active Fu targeting. Moreover, Fu-IO NPs induced efficient apoptosis of lung cancer cells, and thus offer significant anti-cancer functions by potential chemotherapeutic-CDT.
目前正在研发化疗与化学动力疗法（CDT）相结合的方法，以提高当前治疗的诊疗效果和生物安全性。然而，大多数CDT试剂因存在多种成分、胶体稳定性低、载体相关毒性、活性氧生成不足以及靶向效果差等复杂问题而受到限制。为克服这些问题，开发了一种由岩藻多糖（Fu）和氧化铁（IO）纳米颗粒（NPs）组成的新型纳米平台，以简便的自组装方式实现化疗与CDT协同治疗，该NPs由Fu和IO组成，其中Fu不仅用作潜在的化疗药物，还旨在稳定IO并靶向P-选择素过表达的肺癌细胞，从而产生氧化应激，进而增强CDT疗效。Fu-IO NPs的直径在300 nm以下，大小合适，有利于癌细胞对其摄取。显微镜和MRI数据证实，由于Fu的主动靶向作用，NPs被肺癌细胞摄取。此外，Fu-IO NPs诱导肺癌细胞有效凋亡，因此通过潜在的化疗-CDT发挥显著的抗癌作用。
